Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep-Oct;1(5):422-31.
doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15.

Golimumab

Sohini Mazumdar  1 , David Greenwald
Affiliations
Review

Golimumab

Sohini Mazumdar et al. MAbs. 2009 Sep-Oct.

Abstract

Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.

PubMed Disclaimer

Figures

Table 1
Table 1
Clinical studies in approved indications: Rheumatoid arthritis
See this image and copyright information in PMC

References

    1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis mechanism of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279. - PubMed
    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:15–25. - PubMed
    1. Shealy D, Cai A, Lacy E, Nesspor T, Staquet K, Johns L, et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFα. Ann Rheum Dis. 2007;66:151. - PubMed
    1. Martin PL, Cornacoff J, Prabhakar U, Lohr T, Treacy G, Sutherland JE, et al. Preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-α in cynomolgus macaques. J Immunotoxicol. 2004;1:131–139. - PubMed
    1. Martin PL, Oneda S, Treacy G. Effects of an anti-TNFα monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138–149. - PubMed

MeSH terms